Quantum BioPharma Licensee Unbuzzd Wellness to Host Investor Webinar on September 16, 2025 at 1:30 PM PT

About this update from Quantum Biopharma Ltd. Subordinate Voting Shares Class B

[{"type":"text","content":"Quantum BioPharma Licensee Unbuzzd Wellness to Host Investor Webinar on September 16, 2025 at 1:30 PM PT\n\n\n\n TORONTO, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“\n \n Quantum BioPharma\n \n ” or the “\n \n Company\n \n ”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announced its licensee – Unbuzzd Wellness Inc. (the \"\n \n Company\n \n \" or \"\n \n Unbuzzd\n \n \"), the company behind unbuzzd\n \n TM\n \n — the scientifically-proven and game-changing beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms, will host an Investor Webinar on Tuesday, September 16, 2025 at 1:30 p.m. Pacific time, 4:30 p.m. Eastern Standard Time.\n \n\n During the webinar, Unbuzzd CEO John Duffy, Advisor Jason Sawyer, Medical Director Dr. Eric Hoskins, and Board Co-Chair Gerry David will discuss the current Reg D 506(c) investment opportunity for its scientifically-proven beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms. Investors will also learn about Unbuzzd Wellness’ strategies to accelerate direct-to-consumer, distributor, and retail sales. A question-and-answer session will follow the presentation. To register, please click here\n \n link\n \n .\n \n\n CEO John Duffy commented, “We look forward to this opportunity to engage and inform current and potential investors about the rapidly expanding global market for unbuzzd. We will review the science behind how it works, and discuss results from our double-blind, placebo-controlled clinical study. We will also discuss the current opportunity to invest in our Regulation D 506(c) offering where we expect to raise up to US$5.0 million to support our aggressive expansion plans, and possible initial public offering.”\n \n\n Quantum BioPharma shareholders will not be diluted by this offering.\n \n\n A replay of the webinar will be available upon request by contacting\n \n [email protected]\n \n or by calling 518-862-5993. To learn more about the...

More updates from Quantum Biopharma Ltd. Subordinate Voting Shares Class B